Celadon Pharmaceuticals (LSE:CEL) Change In Receivables : €0.13 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals Change In Receivables?

Celadon Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2023 was €-0.22 Mil. It means Celadon Pharmaceuticals's Accounts Receivable increased by €0.22 Mil from Jun. 2023 to Dec. 2023 .

Celadon Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was €0.13 Mil. It means Celadon Pharmaceuticals's Accounts Receivable declined by €0.13 Mil from Dec. 2022 to Dec. 2023 .

Celadon Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2023 was €0.09 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Celadon Pharmaceuticals's Days Sales Outstanding for the six months ended in Dec. 2023 was 203.56.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Celadon Pharmaceuticals's liquidation value for the six months ended in Dec. 2023 was €-5.43 Mil.

Celadon Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Celadon Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals Change In Receivables Chart

Celadon Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-0.21

0.20

-1.13

0.13

Celadon Pharmaceuticals Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial			-0.19	-0.45	-0.69	0.34	-0.22

Celadon Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.13 Mil.

Celadon Pharmaceuticals (LSE:CEL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Celadon Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.087	/	0.078	*	91
=	203.56

2. In Ben Graham's calculation of liquidation value, Celadon Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Celadon Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1.461	-	7.011	+	0.75 * 0.087	+	0.5 * 0.116
=	-5.43

Celadon Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Celadon Pharmaceuticals (LSE:CEL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

32-33 Cowcross Street, London, GBR, EC1M 6DF

Website

https://www.celadonpharma.co.uk

Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines